Generative Chemistry and De Novo Molecule Design

De novo molecular design asks a system to propose structures rather than merely score a fixed list. Generative models can represent molecules as SMILES strings, molecular graphs, or three-dimensional atom configurations. Approaches include autoregressive sequence models, variational autoencoders, graph-based models, and diffusion methods. The representation shapes which structures can be generated and which chemical constraints are easy to enforce. A design task defines objectives. A model may optimize predicted target activity, solubility, selectivity, or other properties, subject to constraints such as retaining a scaffold or staying within a desired size range. A reward function can combine prediction scores and penalties. The optimizer may exploit weaknesses in those predictors, generating molecules with high predicted reward but poor chemical plausibility or out-of-domain structure. Generated candidates need several checks: valid molecular graphs, reasonable valence and stereochemistry, novelty relative to known compounds, similarity to prior training examples, property ranges, toxicity flags, and synthetic feasibility. Validity alone is not evidence of usefulness. Novelty depends on the reference database and standardization choices. Predicted synthesizability scores are heuristics and cannot replace route planning or chemist review. Evaluation should include diversity and benchmark design, not just the best predicted score. Compare against simple baselines, use held-out assays where possible, and report how duplicates and invalid molecules are handled. Property predictors should be calibrated or at least validated in the target chemical domain. Iterative synthesis and testing can update models, but selection bias and failed experiments need to be recorded. Generative chemistry is best used to propose and prioritize hypotheses for experimental work. It does not guarantee a molecule can be synthesized, bind a target, behave safely, or become a drug. Experimental feasibility, biological validation, and multidisciplinary judgment remain essential.